Literature DB >> 32500004

Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience.

Adam R Wolfe1, Dukagjin Blakaj1, Nyall London2, Adriana Blakaj3, Brett Klamer4, Jeff Pan4, Paul Wakely5, Luciano Prevedello6, Marcelo Bonomi7, Aashish Bhatt1, Raju Raval1, Joshua Palmer1, Daniel Prevedello4, Mauricio Gamez1, Ricardo Carrau2.   

Abstract

Purpose  Olfactory neuroblastoma (ONB) is a rare head and neck cancer believed to be originated from neural crest cells of the olfactory membrane located in the roof of the nasal fossa. This study evaluates clinical outcomes and failure patterns in ONB patients of those patients treated with surgical resection at a high-volume tertiary cancer center. Methods and Materials  Thirty-nine ONB patients who underwent surgical resection at our institution from 1996 to 2017 were retrospectively identified. Univariate, multivariate, and survival analysis were calculated using Cox regression analysis and Kaplan-Meier log-rank. Results  Median follow-up time was 59 months (range: 5.2-236 months). The median overall survival (OS) and disease-free survival (DFS) for the entire cohort were 15 and 7.6 years, respectively. The 5-year cumulative OS and DFS were 83 and 72%, respectively. The 5-year OS for low Hyams grade (LHG) versus high Hyams grade (HHG) was 95 versus 61% ( p  = 0.041). LHG was found in 66% of the early Kadish stage patients compared with 28% in the advanced Kadish stage patients ( p  = 0.057). On multivariate analysis, HHG and positive node status predicted for worse OS and only HHG predicted for worse DFS. Of note, five patients (all Kadish stage A) who received surgical resection alone had no observed deaths or recurrences with a median follow-up of 44 months (range: 5-235 months). Conclusion  In this retrospective cohort, patients with positive nodes or HHG have significantly worse clinical outcomes. Future studies should explore treatment intensification for HHG or positive nodes. © Thieme Medical Publishers.

Entities:  

Keywords:  IMRT; olfactory neuroblastoma; radiation therapy

Year:  2019        PMID: 32500004      PMCID: PMC7253300          DOI: 10.1055/s-0039-1692479

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  31 in total

1.  Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.

Authors:  Daniel Jethanamest; Luc G Morris; Andrew G Sikora; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

Review 2.  Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.

Authors:  E A McElroy; J C Buckner; J E Lewis
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

Review 3.  Olfactory neuroblastoma.

Authors:  Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2009-07-16

4.  Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature.

Authors:  Piotr Czapiewski; Michał Kunc; Adam Gorczyński; Johannes Haybaeck; Krzysztof Okoń; Joanna Reszec; Anna Lewczuk; Jaroslaw Dzierzanowski; Joanna Karczewska; Wojciech Biernat; Mario Turri-Zanoni; Paolo Castelnuovo; Cecilia Taverna; Alessandro Franchi; Stefano La Rosa; Fausto Sessa; Günter Klöppel
Journal:  Hum Pathol       Date:  2018-05-25       Impact factor: 3.466

5.  Endonasal endoscopic resection of olfactory neuroblastoma: an 11-year experience.

Authors:  Gary L Gallia; Anthony O Asemota; Ari M Blitz; Andrew P Lane; Wayne Koch; Douglas D Reh; Masaru Ishii
Journal:  J Neurosurg       Date:  2018-08-03       Impact factor: 5.115

6.  Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy.

Authors:  Markus M Fitzek; Allan F Thornton; Marc Varvares; Marek Ancukiewicz; James Mcintyre; Judy Adams; Stanley Rosenthal; Michael Joseph; Philip Amrein
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

7.  The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck.

Authors:  Wen Jiang; Abdallah S R Mohamed; Clifton David Fuller; Betty Y S Kim; Chad Tang; G Brandon Gunn; Ehab Y Hanna; Steven J Frank; Shirley Y Su; Eduardo Diaz; Michael E Kupferman; Beth M Beadle; William H Morrison; Heath Skinner; Stephen Y Lai; Adel K El-Naggar; Franco DeMonte; David I Rosenthal; Adam S Garden; Jack Phan
Journal:  Pract Radiat Oncol       Date:  2015-11-10

8.  Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.

Authors:  M Preusser; M Hutterer; M Sohm; O Koperek; K Elandt; K Dieckmann; D Prayer; C Marosi
Journal:  J Neurooncol       Date:  2009-10-10       Impact factor: 4.130

9.  Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma.

Authors:  Ling Mao; Yuan-Peng Xia; Yu-Nan Zhou; Ruo-Lian Dai; Xue Yang; Yan-Jun Wang; Shu-Jie Duan; Xian Qiao; Yuan-Wu Mei; Bo Hu
Journal:  Oncology       Date:  2009-09-07       Impact factor: 2.935

10.  Combined modality therapy of esthesioneuroblastoma.

Authors:  J Nicolas McLean; Sunjay R Nunley; Carmen Klass; Charles Moore; Susan Müller; Peter A S Johnstone
Journal:  Otolaryngol Head Neck Surg       Date:  2007-06       Impact factor: 3.497

View more
  1 in total

Review 1.  The genomics and epigenetics of olfactory neuroblastoma: A systematic review.

Authors:  Raman Preet Kaur; Evgeny Izumchenko; Dukagjin M Blakaj; Nikol Mladkova; Matt Lechner; Thomas L Beaumont; Charalampos S Floudas; Gary L Gallia; Nyall R London
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.